Quid Pro Quo (QPQ) Tracker
← Back to Influence Map
Entity DossierPerson

David Ricks

Chairman and CEO of Eli Lilly since 2017. Has led the company through the GLP-1/obesity drug revolution while facing scrutiny over insulin pricing.

Tracked direct giving

$30,800

Connections

1

The Money Trail

How money flowed from David Ricks

$31K
3 transactions across 3 counterparties
sum of 3 tracked donations shown

David Ricks directed $25K to GROW THE MAJORITY.

Sep 2024individual

David Ricks directed $3K to GUTHRIE FOR CONGRESS.

May 2024individual

David Ricks directed $3K to BANKS FOR SENATE.

Jul 2023individual
$31K tracked across 3 counterparties (sum of 3 tracked donations shown)
PAC Chain Attribution

Where David Ricks’s money ended up

Attributed amounts are modeled estimates of how money flowed through intermediary PACs, computed by proportional apportionment of FEC-reported transactions. They are not reported transactions themselves. How we compute this

$258
modeled estimate
1 path across 1 counterparty
$258modeled estimateattributed to MIKE JOHNSON FOR LOUISIANA
2024 cycle1 path1 hopMedium confidence

smallest single documented leg $25K (larger than the modeled estimate: the leg carried money from other sources too)

$258 attributed (modeled estimate) across 1 path·Up to 1 hop deep·Source FEC filings (Schedules A, B, E)·How we compute this
Connection Graph
0 nodes · 0 edgesHover for labels · Double-click to expand
Loading graph...
Person
Organization
PAC
Gov Body
Legislature
Think Tank
Industry
Outcome

Click a node to see details

Double-click to expand its connections

Donations Given and Outside Spending

Largest 50 records. Rows badged “Spent to support” or “Spent to oppose” are independent expenditures this entity paid to vendors for or against the named candidate. That money was not given to them.

RecipientAmountDateCycle
GROW THE MAJORITY$25,000Sep 11, 20242024
GUTHRIE FOR CONGRESS$3,300May 27, 20242024
BANKS FOR SENATE$2,500Jul 21, 20232024

Relationships

TypeConnected ToDetailsSource
Worked forEli Lilly &Chairman and CEO of Eli Lilly since 2017Editorial